Abstract:Chimeric antigen receptor (CAR) T cell therapy, while highly efficacious for the treatment of certain haematological malignancies, remains ineffective in solid cancers. This can be attributed to various factors, including immunosuppression and heterogeneous expression of targetable tumor antigens. Our previous work (Lai et al. 2020, Nature Immunology) demonstrated that engineering CAR T cells to engage host immunity is key to effectively treating heterogenous tumors. "Armouring" CAR T cells to express proinflammatory cytokines is a promising strategy to engage endogenous anti-tumor immunity. However, conventional armouring approaches that utilize a synthetic promoter to drive cytokine expression (e.g. NFAT promoter) lead to systemic expression of transgenes, which can cause severe clinical toxicities when potent cytokines such as IL-12 are employed. In the current work, we engineered CAR T cells to express anti-tumor factors under the transcriptional control of tumor-specific promoters, and hypothesised that this would enhance the safety and efficacy of armoured CAR T cells (Chen et al. in revision, Cell). Genome-wide RNA-sequencing was used to identify genes in CAR T cells with tumor-specific expression. A novel CRISPR/Cas9-mediated homology directed repair strategy was then employed to knock in (KI) anti-cancer factors into these gene loci. NR4A2 was identified as the promoter with the highest degree of tumor-site restriction and T cells were subsequently engineered to express cytokines from this promoter. This approach was applied to syngeneic CAR T and OT-I murine models that enable clinically relevant assessment of efficacy and safety. CRISPR-engineered primary murine and human CAR T cells exhibited gene KI efficiency of ∼50%. Integrating proinflammatory cytokines such as IL-12 into the NR4A2 promoter led to antigen-specific induction of transgene expression in tumor cocultures, and tumor-restricted expression in vivo. Importantly, this strategy achieved significantly improved tumor-site specific expression of transgenes relative to the NFAT promoter system. Tumor-specific induction of IL-12 improved anti-tumor efficacy leading to eradication of established tumors and activation of host immunity/epitope spreading that enabled effective treatment of heterogenous tumors. Importantly, this approach did not lead to significant systemic expression of IL-12, and provided a favourable safety profile. We were able to demonstrate that this approach was equally scalable as conventional CAR T cell generation protocols and could be applied to either autologous patient-derived CAR T cells or through a CRISPR Knock-In approach to generate CAR T from allogenic health donor-derived PBMCs. We therefore posit that this technology has the potential to enable the armoring of CAR T cells with cargos that are highly potent and require exquisite tumor-site specific expression of transgenes. Citation Format: Paul Beavis. CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-02.

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

CLDN6 CAR-T cell therapy of relapsed/refractory solid tumors ± a CLDN6-encoding mRNA vaccine: Dose escalation data from the BNT211-01 phase 1 trial using an automated product.

The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function

SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137

Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells.

Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancer

Enhancing anti-gastrointestinal cancer activities of CLDN18.2 CAR-T armored with novel synthetic NKG2D receptors Containing DAP10 and DAP12 signaling domains

NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer

Synergically enhanced anti-tumor immunity of in vivo CAR by circRNA vaccine boosting

Abstract 1435: Utilization of CLDN18.2 syngeneic mouse models to study chimeric antigen receptor T cells in immunocompetent mice

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments

Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer

Abstract 1319: In vivo programming of natural killer cells and T cells using mRNA delivered cytotoxic chimeric antigen receptors

In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism.

Phase I Trial Of Claudin 18.2-Specific Chimeric Antigen Receptor T Cells For Advanced Gastric And Pancreatic Adenocarcinoma.

Abstract PR-02: CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells

Research advance in lipid nanoparticle-mRNA delivery system and its application in CAR-T cell therapy

Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

Non-viral vectors for chimeric antigen receptor immunotherapy

Abstract 1321: In vivo immune cell programming using mRNA-LNP chimeric antigen receptors